ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Buys AP214 Hormone From Action Pharma For $110 Million

DOW JONES NEWSWIRES Abbott Laboratories (ABT) took another step to enhance its renal-care pipeline by agreeing to acquire AP214, a hormone analogue that may prevent acute kidney injury during cardiac surgery, from Action Pharma A/S for $110 million in cash. The health-care company has been on a buying spree in recent years in order to reduce its dependence on the anti-inflammatory Humira as the drug's U.S. patent expires in late 2016. Abbott also is in the midst of separating into two publicly traded companies: a medical-products business and a pharmaceutical company to be named AbbVie. Abbott will acquire all global rights to develop and market AP214, and will be responsible for funding all future development and commercialization activities. No later milestone payments or royalties will be paid to the Danish biotech company Action Pharma. Abbott currently has two investigational treatments in development for chronic kidney disease: Bardoxolone, which is in Phase 3 development with Reata Pharmaceuticals, and Atrasentan, a compound discovered by Abbott being evaluated in a Phase 2b study. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Abbott Labs (ABT)
DateTimeHeadline
04/23/201513:04:14Abbott Laboratories Price Target Raised to $48.00 at JPMorgan...
04/23/201509:37:24Abbott Laboratories's Buy Rating Reaffirmed at Deutsche Bank...
04/23/201509:27:50Abbott Laboratories Stock Rating Reaffirmed by Barclays (ABT)
04/23/201504:30:47Stifel Nicolaus Boosts Abbott Laboratories Price Target to $53.00...
04/22/201512:56:09Correction to Abbott Labs Earnings Headlines, Articles
04/22/201512:45:50The Rise of the 'Stichting,' an Obscure Takeover Defense
04/22/201510:10:09Abbott Labs Reports Better-Than-Expected Profit
04/22/201509:46:46Abbott Labs Reports Better-Than-Expected Profit -- Update
04/22/201509:37:05Abbott Labs Reports Better-Than-Expected Profit
04/22/201508:08:51Current Report Filing (8-k)
04/22/201507:45:00Abbott Reports First-Quarter 2015 Results
04/15/201509:00:00New Blood Glucose Meter Provides People with Diabetes an Accurate...
04/14/201509:00:00Abbott and Sekisui Collaborate to Offer Coagulation Testing for...
04/14/201509:00:00Abbott and Sekisui Collaborate to Offer Coagulation Testing for...
04/13/201510:00:00Boston Athletic Association And Abbott Announce Multiple-Year...
04/13/201504:58:57Taking A Financial Mulligan With Dividend Investing
04/10/201517:01:51Current Report Filing (8-k)
04/08/201513:48:46Mylan Bids $205/Share for Generic Drug Maker Perrigo--4th Update
04/08/201512:48:19Mylan Bids $205/Share for Generic Drug Maker Perrigo--3rd Update
04/08/201512:40:10Mylan Bids $205/Share for Generic Drug Maker Perrigo--3rd Update

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad